EHRA 2023: Late-Breaking Science Video Collection
Published: 18 April 2023
2m 38sPart 1 | Session 5 TEMPO-HCM: Extended ECG Monitoring in HCM
3m 37sPart 1 | Session 6 Conformable PVI Catheter for Pulmonary Vein Isolation
3m 54sPart 1 | Session 7 BRUGADA Randomized: Epidcardial Ablation to Prevent Sudden Death
6m 25sPart 2 | Session 1 5 Trials That Will Change Your Practice With Dr Sohaib
6m 24sPart 2 | Session 2 4 Trials That Will Change Your Practice With Dr Di Biase
54sPart 3 | Session 1 Dr Bergonti: Pulsed-Field Ablation & Reasons to Research
1m 52sPart 3 | Session 2 Dr Bruce Wilkoff: Therapy Morbidity and Advice to Young Researchers
31sPart 3 | Session 3 Dr Carlo Pappone: Advice to Early-Career Electrophysiologists
28sPart 3 | Session 4 Dr Juan Caro Codon: Building a Team For Success
4m 23sPart 1 | Session 1 POTTER: Oesophageal Fistulae in Catheter Ablation Patients Roland R Tilz
4m 26sPart 1 | Session 2 AdaptResponse: AdaptivCRT® Algorithm in Synchronized LV Pacing Bruce Wilkoff
6m 49sPart 1 | Session 3 MANIFEST-PF: Real-world Experience of PFA in Commercial Practice Vivek Reddy
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
In these concise overviews, selected faculty provide their thoughts on the most impactful trials from EHRA 2023.
Behind the Heart
Watch our Behind the Heart series to learn more about the personal perspectives of the investigators behind top trials in cardiovascular science.
About the episode
EHRA 23 - Dr Marco Bergonti (Istituto Cardiocentro Ticino, CH) to discuss the key takeaways from the ANTWOORD II Trial.
In this study, 605 heart failure patients undergoing atrial fibrillation ablation were enrolled to receive an ANTWERP Score, which aimed to predict LVEF recovery. 70% of patients were categorised as 'responders', patients identified as those who could benefit the most from AF ablation.
Results suggest that responders to the study achieved 10 times less deaths and heart transplantations, 10 times less heart failure hospitalisations and 8 times more positive left ventricular remodeling.
- Can you provide a brief overview of the ANTWOORD I trial and explain the research question that ANTWOORD II aims to address?
- Could you elaborate on the ANTWERP scoring system and how it is used in the study?
- Can you describe the study design, entry criteria, and patient population in detail?
- What were the main findings of the study and what conclusions can be drawn from them?
- What are the clinical implications of the study?
- What are some limitations of the study that should be considered?
- What are the next steps?
Recorded from EHRA 2023, Barcelona.